Matritech to Report Second Quarter 2007 Financial Results on July 31, 2007
July 17 2007 - 9:00AM
Business Wire
Matritech (AMEX:MZT) announced today that it will release its
second quarter 2007 earnings results before market opening on July
31, 2007. The company has scheduled a conference call at 8:30 a.m.
(ET) that day to discuss the results and provide a company update.
The call will be webcast and can be accessed on the Matritech web
site at www.matritech.com. Conference Call Dial-in Number To access
the conference call by phone, the dial-in number in the United
States is 800-591-6945. The International number is 617-614-4911.
The participant pass code is 18241894. The webcast will also be
distributed over CCBN's Investor Distribution Network to both
institutional and individual investors. About Matritech Matritech
is using its patented proteomics technology to develop diagnostics
for the detection of a variety of cancers. The Company's first two
products, the NMP22� Test Kit and NMP22� BladderChek� Test, have
been FDA approved for the monitoring and diagnosis of bladder
cancer. The NMP22 BladderChek Test is based on Matritech's
proprietary nuclear matrix protein (NMP) technology, which
correlates levels of NMPs in body fluids to the presence of cancer.
Beginning with a patent portfolio licensed exclusively from the
Massachusetts Institute of Technology (MIT), Matritech�s patent
portfolio has grown to 14 other U.S. patents. In addition to the
NMP22 protein marker utilized in the NMP22 Test Kit and NMP22
BladderChek Test, the Company has discovered other proteins
associated with cervical, breast, prostate, and colon cancer. The
Company�s goal is to utilize protein markers to develop, through
its own research staff and through strategic alliances, clinical
applications to detect cancer. More information about Matritech is
available at www.matritech.com. Statement under the Private
Securities Litigation Reform Act Any forward-looking statements in
this press release including those related to the Company's
expectations regarding future sales of the Company�s products,
sales in specific target markets, future products under development
by the Company or third parties, and business prospects are subject
to a number of risks and uncertainties, many of which are beyond
the Company�s control. Please refer to the risk factors detailed in
the Company�s periodic reports and registration statements as filed
with the Securities and Exchange Commission. These forward-looking
statements are neither promises nor guarantees. There can be no
assurance that the Company�s expectations for its products or
future financial performance will be achieved. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Matritech
undertakes no responsibility to revise or update any such
forward-looking information.
Matritech (AMEX:MZT)
Historical Stock Chart
From May 2024 to Jun 2024
Matritech (AMEX:MZT)
Historical Stock Chart
From Jun 2023 to Jun 2024